Branded Legacy Advances FDA Pathway for Intranasal Naloxone with Pre-ANDA Briefing Preparation

Branded Legacy, Inc. (OTC: BLEG) has announced that its subsidiary, BioLegacy Evaluative Group, has begun preparing its FDA Pre-Abbreviated New Drug Application briefing package for a proprietary intranasal naloxone spray. This development follows BioLegacy's provisional patent filing for its air-driven delivery platform, which is designed to offer a cost-effective, scalable solution to the opioid overdose crisis. The submission includes a Target Product Profile for 2 mg and 4 mg naloxone HCl nasal sprays, Chemistry, Manufacturing and Controls specifications, a 60-subject bioequivalence study against Narcan, and human factors testing to ensure accessibility for non-medical users.

The company's intranasal platform aims to replicate Narcan performance while significantly reducing cost and improving global accessibility, according to Kristian Thorlund, Executive Chair of Branded Legacy. This advancement represents a critical step in addressing the ongoing opioid epidemic by potentially making overdose reversal treatments more affordable and widely available. The preparation of the Pre-ANDA briefing package marks a significant regulatory milestone in the development pathway for this alternative naloxone delivery system.

The comprehensive submission package demonstrates the company's commitment to meeting FDA requirements while advancing innovative solutions for public health challenges. The inclusion of human factors testing specifically addresses the need for user-friendly administration by non-medical personnel, which is crucial for emergency overdose situations where immediate intervention can save lives. The bioequivalence study against the established Narcan product provides scientific validation of the platform's effectiveness.

This development comes at a time when opioid overdose deaths continue to pose a significant public health concern globally. The air-driven delivery platform technology could potentially transform access to life-saving naloxone treatments by making them more affordable and easier to distribute. For more information about the company, visit https://BrandedLegacy.com. Additional details about the announcement can be found at https://ibn.fm/UBvl4. The progress in the FDA regulatory pathway represents an important advancement in the fight against opioid overdoses and could have substantial implications for harm reduction strategies worldwide.